Axitinib News and Research

RSS
Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Promising preliminary data for axitinib in metastatic kidney cancer

Promising preliminary data for axitinib in metastatic kidney cancer

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Inlyta receives FDA approval for treatment of advanced kidney cancer

Inlyta receives FDA approval for treatment of advanced kidney cancer

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer second-quarter revenues decrease 1% to $17.0 billion

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer awards $2.1 million grant to NCCN to evaluate axitinib in solid tumors

Pfizer awards $2.1 million grant to NCCN to evaluate axitinib in solid tumors

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment